Impact of Lymphovascular Invasion in Patients With Stage II Colorectal Cancer: A Propensity Score-matched Study.
Lymphovascular invasion
adjuvant chemotherapy
high-risk factor
stage II colorectal cancer
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
11
10
2020
revised:
23
10
2020
accepted:
27
10
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Whether lymphovascular invasion (LVI) is a high-degree risk factor in stage II colorectal cancer has not been fully clarified, as different results have been reported in the literature. If LVI is a risk factor, postoperative chemotherapy may be recommended. The purpose of this study was to evaluate the impact of lymphovascular invasion on disease recurrence and patient prognosis in conjunction with stage II colorectal cancer (CRC). A total of 636 patients with stage II CRC, each undergoing radical resection between April 2007 and December 2015, were selected for the study. Subjects with or without venous or lymphatic invasion were assigned to positive and negative groups, respectively. We then compared overall survival (OS) and disease-free survival (DFS) using propensity score matching. After matching (n=226, each group), OS and DFS were found to be significantly lower (OS: p=0.047; DFS: p=0.004) in patients positive (vs. negative) for venous invasion. However, the same was not true of lymphatic invasion. After matching, positive and negative groups (n=92, each) did not significantly differ in terms of OS (p=0.951) or DFS (p=0.258). In patients with stage II CRC, venous invasion proved to be a significant high-degree risk factor that may warrant adjuvant chemotherapy.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Whether lymphovascular invasion (LVI) is a high-degree risk factor in stage II colorectal cancer has not been fully clarified, as different results have been reported in the literature. If LVI is a risk factor, postoperative chemotherapy may be recommended. The purpose of this study was to evaluate the impact of lymphovascular invasion on disease recurrence and patient prognosis in conjunction with stage II colorectal cancer (CRC).
PATIENTS AND METHODS
METHODS
A total of 636 patients with stage II CRC, each undergoing radical resection between April 2007 and December 2015, were selected for the study. Subjects with or without venous or lymphatic invasion were assigned to positive and negative groups, respectively. We then compared overall survival (OS) and disease-free survival (DFS) using propensity score matching.
RESULTS
RESULTS
After matching (n=226, each group), OS and DFS were found to be significantly lower (OS: p=0.047; DFS: p=0.004) in patients positive (vs. negative) for venous invasion. However, the same was not true of lymphatic invasion. After matching, positive and negative groups (n=92, each) did not significantly differ in terms of OS (p=0.951) or DFS (p=0.258).
CONCLUSION
CONCLUSIONS
In patients with stage II CRC, venous invasion proved to be a significant high-degree risk factor that may warrant adjuvant chemotherapy.
Identifiants
pubmed: 33402505
pii: 35/1/525
doi: 10.21873/invivo.12287
pmc: PMC7880780
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-531Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Oncol. 2004 Aug 15;22(16):3395-407
pubmed: 15199087
Tumori. 2014 Mar-Apr;100(2):143-8
pubmed: 24852857
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
Clin Cancer Res. 2016 Jul 15;22(14):3488-98
pubmed: 27029492
Nat Rev Clin Oncol. 2011 Sep 13;8(10):574-6
pubmed: 21912416
Int J Colorectal Dis. 2014 Oct;29(10):1237-43
pubmed: 25024041
Dis Colon Rectum. 2010 Apr;53(4):377-84
pubmed: 20305435
Med Sci Monit. 2019 Aug 13;25:6043-6050
pubmed: 31408453
Ann Surg Oncol. 2007 Feb;14(2):470-7
pubmed: 17103258
ANZ J Surg. 2014 Nov;84(11):837-41
pubmed: 24224835
Cancer. 2000 Apr 1;88(7):1739-57
pubmed: 10738234
Am J Surg Pathol. 2012 Jan;36(1):66-72
pubmed: 21989343
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
Radiat Oncol J. 2019 Sep;37(3):215-223
pubmed: 31591870
Anticancer Res. 2019 Jun;39(6):2855-2860
pubmed: 31177123
Lancet. 2007 Dec 15;370(9604):2020-9
pubmed: 18083404
Pathobiology. 2015 Sep;82(3-4):113-23
pubmed: 26330352
Dis Colon Rectum. 1990 Jul;33(7):598-601
pubmed: 2361429
J Clin Oncol. 2004 May 15;22(10):1797-806
pubmed: 15067028
Cancer. 1988 Apr 1;61(7):1417-24
pubmed: 3345494